Quantcast

Latest Darbepoetin alfa Stories

2014-08-13 16:26:02

THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp(®) (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B,...

2013-03-11 15:08:13

Phase 3 findings published in NEJM provide answers about treatment with darbepoetin alfa Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients —darbepoetin alfa — does not improve patients' health, nor does it reduce their risk of death from heart failure. Results of the international study were presented at the American College of Cardiology's annual meeting in San...

Recall Notice Issued For Anemia Drug Omontys
2013-02-25 05:22:08

redOrbit Staff & Wire Reports - Your Universe Online Two pharmaceutical companies have issued a recall of their anemia drug Omontys after receiving reports that some kidney dialysis patients had suffered severe allergic reactions after taking the medication. According to the Associated Press (AP), California-based Affymax Inc. and Illinois-based Takeda Pharmaceutical Co. said some of the more than 25,000 patients who had received the drug had experienced adverse effects afterwards,...

2012-01-20 10:45:38

Drugs that treat anemia are critical for many who have kidney disease Highlights     More than 20 million adults in the United States have chronic kidney disease.     Drugs that treat red blood cell deficiencies are critical for maintaining many chronic kidney disease patients' health.     Experts comment on newly released federal recommendations for these drugs. The U.S. Food and Drug Administration (FDA) recently recommended that...

2011-06-24 10:51:00

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), in patients with chronic kidney disease (CKD). The modified language, including changes to the Boxed Warning, provides important new...

2011-06-24 10:47:00

Cites increased risk of cardiovascular events when used to treat chronic kidney disease SILVER SPRING, Md., June 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death. (Logo:...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.